
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc has demonstrated promising advancements in its clinical pipeline, with four active Phase 3 trials for its lead products, including tarcocimab, KSI-501, and KSI-101, and multiple data readouts anticipated through 2026. The company reported an increase in R&D expenses to $50.5 million for the quarter, primarily due to clinical and manufacturing activities, indicative of its ongoing commitment to product development. Encouraging follow-up results from the APEX trial revealed significant improvements in best-corrected visual acuity (BCVA) for patients, which could strengthen the company's position in the competitive biopharmaceutical market for retinal diseases.
Bears say
The financial outlook for Kodiak Sciences is negatively impacted by several critical factors, including the potential failure of its developmental candidates, particularly Tarcocimab, to meet peak commercial revenue estimates due to limitations related to market size and penetration rates. Additionally, the company reported a significant net loss of $61.5 million for the third quarter of 2025, indicating ongoing cash burn that may hinder its ability to fund operations and expand necessary commercialization infrastructure. Furthermore, there are substantial regulatory and clinical risks associated with the approval of its products, as well as pervasive uncertainties regarding the effectiveness of its ABC technology platform, which could jeopardize the future of key pipeline assets.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares